BPG is committed to discovery and dissemination of knowledge
Cited by in F6Publishing
For: Liang R. How I treat and monitor viral hepatitis B infection in patients receiving intensive immunosuppressive therapies or undergoing hematopoietic stem cell transplantation. Blood. 2009;113:3147-3153. [PMID: 19144986 DOI: 10.1182/blood-2008-10-163493] [Cited by in Crossref: 99] [Cited by in F6Publishing: 95] [Article Influence: 7.6] [Reference Citation Analysis]
Number Citing Articles
1 Yağcı M, Suyanı E, Kızıl Çakar M. The Impact of Chemotherapy on Hepatitis B Antibody Titer in Patients with Hematological Malignancies. Turk J Haematol 2015;32:251-6. [PMID: 26376591 DOI: 10.4274/tjh.2013.0342] [Cited by in Crossref: 4] [Cited by in F6Publishing: 5] [Article Influence: 0.8] [Reference Citation Analysis]
2 Larrubia JR. Occult hepatitis B virus infection: a complex entity with relevant clinical implications. World J Gastroenterol. 2011;17:1529-1530. [PMID: 21472115 DOI: 10.3748/wjg.v17.i12] [Cited by in F6Publishing: 6] [Reference Citation Analysis]
3 Sagnelli E, Pisaturo M, Martini S, Filippini P, Sagnelli C, Coppola N. Clinical impact of occult hepatitis B virus infection in immuno–suppressed patients. World J Hepatol. 2014;6:384-393. [PMID: 25018849 DOI: 10.4254/wjh.v6i6.384] [Cited by in F6Publishing: 1] [Reference Citation Analysis]
4 Çakar MK, Suyani E, Sucak GT, Altindal Ş, Aki SZ, Acar K, Yağci M, Rota S, Özenirler S. HBV-related events after allogeneic hematopoetic stem cell transplantatıon in a center from Turkey. Ann Hematol 2013;92:395-402. [PMID: 23143119 DOI: 10.1007/s00277-012-1620-1] [Cited by in Crossref: 1] [Cited by in F6Publishing: 2] [Article Influence: 0.1] [Reference Citation Analysis]
5 Yang CX, Lai WJ, Tang YM. Progress in prevention and treatment of HBV reactivation associated with chemotherapy in malignant tumor patients. Shijie Huaren Xiaohua Zazhi 2016; 24(7): 1048-1053 [DOI: 10.11569/wcjd.v24.i7.1048] [Reference Citation Analysis]
6 Mozessohn L, Chan KK, Feld JJ, Hicks LK. Hepatitis B reactivation in HBsAg-negative/HBcAb-positive patients receiving rituximab for lymphoma: a meta-analysis. J Viral Hepat. 2015;22:842-849. [PMID: 25765930 DOI: 10.1111/jvh.12402] [Cited by in Crossref: 79] [Cited by in F6Publishing: 72] [Article Influence: 11.3] [Reference Citation Analysis]
7 Candotti D, Allain JP. Transfusion-transmitted hepatitis B virus infection. J Hepatol. 2009;51:798-809. [PMID: 19615780 DOI: 10.1016/j.jhep.2009.05.020] [Cited by in Crossref: 115] [Cited by in F6Publishing: 122] [Article Influence: 8.8] [Reference Citation Analysis]
8 Elbedewy TA, Elashtokhy HE, Rabee ES, Kheder GE. Prevalence and chemotherapy-induced reactivation of occult hepatitis B virus among hepatitis B surface antigen negative patients with diffuse large B-cell lymphoma: significance of hepatitis B core antibodies screening. J Egypt Natl Canc Inst. 2015;27:11-18. [PMID: 25716703 DOI: 10.1016/j.jnci.2015.01.004] [Cited by in Crossref: 7] [Cited by in F6Publishing: 8] [Article Influence: 1.0] [Reference Citation Analysis]
9 Pomakova D, Segal BH. Prevention of infection in cancer patients. Cancer Treat Res 2014;161:485-511. [PMID: 24706235 DOI: 10.1007/978-3-319-04220-6_16] [Cited by in Crossref: 4] [Cited by in F6Publishing: 3] [Article Influence: 0.5] [Reference Citation Analysis]
10 Cheng DR, Barton R, Greenway A, Crawford NW. Rituximab and protection from vaccine preventable diseases: applying the evidence to pediatric patients. Expert Rev Vaccines 2016;15:1567-74. [PMID: 27216827 DOI: 10.1080/14760584.2016.1193438] [Cited by in Crossref: 9] [Cited by in F6Publishing: 9] [Article Influence: 1.5] [Reference Citation Analysis]
11 Pei SN, Ma MC, Wang MC, Kuo CY, Rau KM, Su CY, Chen CH. Analysis of hepatitis B surface antibody titers in B cell lymphoma patients after rituximab therapy. Ann Hematol. 2012;91:1007-1012. [PMID: 22273839 DOI: 10.1007/s00277-012-1405-6] [Cited by in Crossref: 62] [Cited by in F6Publishing: 56] [Article Influence: 6.2] [Reference Citation Analysis]
12 Davis JS, Ferreira D, Paige E, Gedye C, Boyle M. Infectious Complications of Biological and Small Molecule Targeted Immunomodulatory Therapies. Clin Microbiol Rev 2020;33:e00035-19. [PMID: 32522746 DOI: 10.1128/CMR.00035-19] [Cited by in Crossref: 11] [Cited by in F6Publishing: 4] [Article Influence: 5.5] [Reference Citation Analysis]
13 Kim H, Hur M, Moon HW, Park CM, Cho JH, Park KS, Lee K, Chang S. Pre- and post-transfusion testing for hepatitis B virus surface antigen and antibody in blood recipients: a single-institution experience in an area of high endemicity. Ann Lab Med. 2012;32:73-78. [PMID: 22259782 DOI: 10.3343/alm.2012.32.1.73] [Cited by in Crossref: 4] [Cited by in F6Publishing: 3] [Article Influence: 0.4] [Reference Citation Analysis]
14 Sagnelli E, Pisaturo M, Martini S, Filippini P, Sagnelli C, Coppola N. Clinical impact of occult hepatitis B virus infection in immunosuppressed patients. World J Hepatol 2014; 6(6): 384-393 [PMID: 25018849 DOI: 10.4254/wjh.v6.i6.384] [Cited by in Crossref: 38] [Cited by in F6Publishing: 38] [Article Influence: 4.8] [Reference Citation Analysis]
15 Cheah CY, Lingaratnam S, Seymour JF. Rituximab for the treatment of follicular lymphoma. Future Oncology 2013;9:1283-98. [DOI: 10.2217/fon.13.134] [Cited by in Crossref: 2] [Cited by in F6Publishing: 1] [Article Influence: 0.2] [Reference Citation Analysis]
16 Pei S, Chen C, Lee C, Wang M, Ma M, Hu T, Kuo C. Reactivation of hepatitis B virus following rituximab-based regimens: a serious complication in both HBsAg-positive and HBsAg-negative patients. Ann Hematol 2010;89:255-62. [DOI: 10.1007/s00277-009-0806-7] [Cited by in Crossref: 148] [Cited by in F6Publishing: 143] [Article Influence: 11.4] [Reference Citation Analysis]
17 Han X, Lv Y, Li Y, Deng J, Qiu Q, Liu N, Zhao S, Liao C. Distribution characteristics of cells in splenomegaly due to hepatitis B-related cirrhotic portal hypertension and their clinical importance. J Int Med Res 2018;46:2633-40. [PMID: 29781346 DOI: 10.1177/0300060518767550] [Reference Citation Analysis]
18 Liao YP, Jiang JL, Zou WY, Xu DR, Li J. Prophylactic antiviral therapy in allogeneic hematopoietic stem cell transplantation in hepatitis B virus patients. World J Gastroenterol 2015; 21(14): 4284-4292 [PMID: 25892880 DOI: 10.3748/wjg.v21.i14.4284] [Cited by in CrossRef: 7] [Cited by in F6Publishing: 7] [Article Influence: 1.0] [Reference Citation Analysis]
19 Tsai SH, Dai MS, Yu JC, Ho CL, Chen YC, Wu YY, Chang PY, Kao WY, Chao TY. Preventing chemotherapy-induced hepatitis B reactivation in breast cancer patients: a prospective comparison of prophylactic versus deferred preemptive lamivudine. Support Care Cancer 2011;19:1779-87. [PMID: 20927554 DOI: 10.1007/s00520-010-1019-2] [Cited by in Crossref: 7] [Cited by in F6Publishing: 7] [Article Influence: 0.6] [Reference Citation Analysis]
20 Pei SN, Chen CH. Risk and prophylaxis strategy of hepatitis B virus reactivation in patients with lymphoma undergoing chemotherapy with or without rituximab. Leuk Lymphoma 2015;56:1611-8. [PMID: 25248874 DOI: 10.3109/10428194.2014.964699] [Cited by in Crossref: 7] [Cited by in F6Publishing: 9] [Article Influence: 1.0] [Reference Citation Analysis]
21 Yaşar DG, Suyanı E, Özenirler S, Sucak GT. Adefovir is effective to promote development of immunity to donor origin hepatitis B virus in an allogeneic transplant recipient: a case report. Transplant Proc 2013;45:833-4. [PMID: 23498831 DOI: 10.1016/j.transproceed.2012.06.082] [Cited by in Crossref: 3] [Cited by in F6Publishing: 2] [Article Influence: 0.3] [Reference Citation Analysis]
22 Dalia S, Suleiman Y, Croy DW, Sokol L. Association of Lymphomagenesis and the Reactivation of Hepatitis B Virus in Non-Hodgkin Lymphoma. Cancer Control 2015;22:360-5. [PMID: 26351893 DOI: 10.1177/107327481502200315] [Cited by in Crossref: 7] [Cited by in F6Publishing: 10] [Article Influence: 1.2] [Reference Citation Analysis]
23 Gentile G, Antonelli G. HBV Reactivation in Patients Undergoing Hematopoietic Stem Cell Transplantation: A Narrative Review. Viruses. 2019;11. [PMID: 31717647 DOI: 10.3390/v11111049] [Cited by in Crossref: 4] [Cited by in F6Publishing: 5] [Article Influence: 1.3] [Reference Citation Analysis]
24 Cobeta García JC, Medrano M. Reactivación de hepatitis B en un paciente con espondiloartritis tras suspender metotrexato y eficacia del tratamiento con antivirales en asociación con adalimumab. Reumatología Clínica 2011;7:200-2. [DOI: 10.1016/j.reuma.2010.08.004] [Cited by in Crossref: 6] [Cited by in F6Publishing: 3] [Article Influence: 0.5] [Reference Citation Analysis]
25 Liang R. Advances in the management and monitoring of extranodal NK/T-cell lymphoma, nasal type. Br J Haematol 2009;147:13-21. [PMID: 19604234 DOI: 10.1111/j.1365-2141.2009.07802.x] [Cited by in Crossref: 50] [Cited by in F6Publishing: 47] [Article Influence: 3.8] [Reference Citation Analysis]
26 Kang BW, Lee SJ, Moon JH, Kim SN, Chae YS, Kim JG, Hwang YJ, Sohn SK. Chronic myeloid leukemia patient manifesting fatal hepatitis B virus reactivation during treatment with imatinib rescued by liver transplantation: case report and literature review. Int J Hematol. 2009;90:383-387. [PMID: 19641858 DOI: 10.1007/s12185-009-0386-2] [Cited by in Crossref: 33] [Cited by in F6Publishing: 35] [Article Influence: 2.5] [Reference Citation Analysis]
27 Tsutsumi Y, Ogasawara R, Kamihara Y, Ito S, Yamamoto Y, Tanaka J, Asaka M, Imamura M. Rituximab administration and reactivation of HBV. Hepat Res Treat 2010;2010:182067. [PMID: 21188195 DOI: 10.1155/2010/182067] [Cited by in Crossref: 6] [Cited by in F6Publishing: 8] [Article Influence: 0.5] [Reference Citation Analysis]
28 Koskinas JS, Deutsch M, Adamidi S, Skondra M, Tampaki M, Alexopoulou A, Manolakopoulos S, Pectasides D. The role of tenofovir in preventing and treating hepatitis B virus (HBV) reactivation in immunosuppressed patients. A real life experience from a tertiary center. Eur J Intern Med. 2014;25:768-771. [PMID: 25037900 DOI: 10.1016/j.ejim.2014.06.028] [Cited by in Crossref: 16] [Cited by in F6Publishing: 17] [Article Influence: 2.0] [Reference Citation Analysis]
29 Shang J, Wang H, Sun J, Fan Z, Huang F, Zhang Y, Jiang Q, Dai M, Xu N, Lin R. A comparison of lamivudine vs entecavir for prophylaxis of hepatitis B virus reactivation in allogeneic hematopoietic stem cell transplantation recipients: a single-institutional experience. Bone Marrow Transplant. 2016;51:581-586. [PMID: 26752138 DOI: 10.1038/bmt.2015.328] [Cited by in Crossref: 25] [Cited by in F6Publishing: 23] [Article Influence: 4.2] [Reference Citation Analysis]
30 Giaccone L, Felicetti F, Butera S, Faraci D, Cerrano M, Dionisi Vici M, Brunello L, Fortunati N, Brignardello E, Bruno B. Optimal Delivery of Follow-Up Care After Allogeneic Hematopoietic Stem-Cell Transplant: Improving Patient Outcomes with a Multidisciplinary Approach. J Blood Med 2020;11:141-62. [PMID: 32523389 DOI: 10.2147/JBM.S206027] [Cited by in Crossref: 3] [Cited by in F6Publishing: 1] [Article Influence: 1.5] [Reference Citation Analysis]
31 Candotti D, Allain JP. Molecular virology in transfusion medicine laboratory. Blood Transfus. 2013;11:203-216. [PMID: 23356973 DOI: 10.2450/2012.0219-12] [Cited by in F6Publishing: 5] [Reference Citation Analysis]
32 Georgiadou SP, Dalekos GN. Which level of immunosuppression is harmful for occult hepatitis B virus infection?: ‘A million dollar’ answer. Liver International 2009;29:1127-8. [DOI: 10.1111/j.1478-3231.2009.02063.x] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.1] [Reference Citation Analysis]
33 Kato H, Kato K, Kim SW, Fukuda T, Mori T, Sawa M, Ohno Y, Yoshioka S, Iwato Y, Taji H, Onizuka M, Kurahashi S, Ichinohe T, Suzumiya J, Suzuki R. Clinical outcomes of hepatitis B or C virus infections in patients with malignant lymphoma receiving autologous stem cell transplantation: on behalf of the Adult Lymphoma Working Group of the Japan Society for Haematopoietic Cell Transplantation (JSHCT). Br J Haematol 2019;186:e170-5. [PMID: 31206602 DOI: 10.1111/bjh.16050] [Reference Citation Analysis]
34 Milazzo L, Corbellino M, Foschi A, Micheli V, Dodero A, Mazzocchi A, Montefusco V, Zehender G, Antinori S. Late onset of hepatitis B virus reactivation following hematopoietic stem cell transplantation: successful treatment with combined entecavir plus tenofovir therapy. Transpl Infect Dis. 2012;14:95-98. [PMID: 21749588 DOI: 10.1111/j.1399-3062.2011.00659.x] [Cited by in Crossref: 14] [Cited by in F6Publishing: 15] [Article Influence: 1.3] [Reference Citation Analysis]
35 Torres HA, Davila M. Reactivation of hepatitis B virus and hepatitis C virus in patients with cancer.Nat Rev Clin Oncol. 2012;9:156-166. [PMID: 22271089 DOI: 10.1038/nrclinonc.2012.1] [Cited by in Crossref: 107] [Cited by in F6Publishing: 90] [Article Influence: 10.7] [Reference Citation Analysis]
36 Marinone C, Mestriner M. HBV disease: HBsAg carrier and occult B infection reactivation in haematological setting. Dig Liver Dis. 2011;43 Suppl 1:S49-S56. [PMID: 21195372 DOI: 10.1016/s1590-8658(10)60692-5] [Cited by in Crossref: 14] [Cited by in F6Publishing: 6] [Article Influence: 1.3] [Reference Citation Analysis]
37 Idilman R, Arat M. Evaluation and management of hepatitis B virus infection in hematopoietic stem cell transplantation: before and after transplantation. Expert Rev Anti Infect Ther 2011;9:641-52. [PMID: 21819330 DOI: 10.1586/eri.11.79] [Cited by in Crossref: 9] [Cited by in F6Publishing: 9] [Article Influence: 1.0] [Reference Citation Analysis]
38 Manzano-Alonso ML, Castellano-Tortajada G. Reactivation of hepatitis B virus infection after cytotoxic chemotherapy or immunosuppressive therapy. World J Gastroenterol 2011; 17(12): 1531-1537 [PMID: 21472116 DOI: 10.3748/wjg.v17.i12.1531] [Cited by in CrossRef: 56] [Cited by in F6Publishing: 56] [Article Influence: 5.1] [Reference Citation Analysis]
39 Frange P, Leruez-ville M, Neven B, Mascard L, Moshous D, Touzot F, Heritier S, Chaix M, Cavazzana M, Casanova J, Fischer A, Blanche S. Safety of hematopoietic stem cell transplantation from hepatitis B core antibodies-positive donors with low/undetectable viremia in HBV-naïve children. Eur J Clin Microbiol Infect Dis 2014;33:545-50. [DOI: 10.1007/s10096-013-1982-x] [Cited by in Crossref: 5] [Cited by in F6Publishing: 5] [Article Influence: 0.6] [Reference Citation Analysis]
40 Capezzuto C, Franchi E, Urbani S, Romanò L, Franchini M. Occult hepatitis B in blood donors: a description of two cases. Blood Transfus 2010;8:297-302. [PMID: 20967173 DOI: 10.2450/2010.0119-09] [Cited by in F6Publishing: 1] [Reference Citation Analysis]
41 Türker K, Albayrak M, Öksüzoğlu B, Balc E, Oğan MC, Iskender G, Altuntaş F. Entecavir as a first-line treatment for hepatitis B virus reactivation following polychemotherapy for chronic lymphocytic leukemia and invasive ductal carcinoma: a report of two cases and review of the literature. Eur J Gastroenterol Hepatol 2015;27:39-45. [PMID: 25076063 DOI: 10.1097/MEG.0000000000000115] [Cited by in Crossref: 5] [Cited by in F6Publishing: 3] [Article Influence: 0.7] [Reference Citation Analysis]
42 Hammond SP, Ho VT, Marty FM. Hepatitis B virus vaccination after allogeneic hematopoietic cell transplantation prevents post-transplant HBV reactivation. Transplant Cell Ther 2022:S2666-6367(22)01197-6. [PMID: 35413458 DOI: 10.1016/j.jtct.2022.04.004] [Reference Citation Analysis]
43 Dyson JK, Hudson M, McPherson S. Lesson of the month 2: Severe reactivation of hepatitis B after immunosuppressive chemotherapy. Clin Med (Lond). 2014;14:551-555. [PMID: 25301924 DOI: 10.7861/clinmedicine.14-5-551] [Cited by in Crossref: 4] [Cited by in F6Publishing: 2] [Article Influence: 0.7] [Reference Citation Analysis]
44 Pruitt AA. Nervous system viral infections in immunocompromised hosts. Handb Clin Neurol 2014;123:685-704. [PMID: 25015512 DOI: 10.1016/B978-0-444-53488-0.00034-1] [Cited by in Crossref: 5] [Cited by in F6Publishing: 3] [Article Influence: 0.6] [Reference Citation Analysis]
45 Federico A, Brancaccio G, Dallio M, Iodice P, Fabozzi A, Del Prete S, Ciardiello F, Loguercio C, Gaeta GB. Reactivation of hepatitis B virus in cancer patients treated with chemotherapy for solid tumors. Is the prophylaxis really required? Dig Liver Dis 2017;49:197-201. [PMID: 27899262 DOI: 10.1016/j.dld.2016.11.004] [Cited by in Crossref: 4] [Cited by in F6Publishing: 4] [Article Influence: 0.7] [Reference Citation Analysis]
46 Cooper N, Bussel JB. The Long-term Impact of Rituximab for Childhood Immune Thrombocytopenia. Curr Rheumatol Rep 2010;12:94-100. [DOI: 10.1007/s11926-010-0090-5] [Cited by in Crossref: 22] [Cited by in F6Publishing: 19] [Article Influence: 1.8] [Reference Citation Analysis]
47 Lee S. Use of TNF Inhibitor in Particular Clinical Settings. J Korean Rheum Assoc 2009;16:264. [DOI: 10.4078/jkra.2009.16.4.264] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.1] [Reference Citation Analysis]
48 Navarro R, Concha-Garzón MJ, Castaño C, Casal C, Guiu A, Daudén E. Outcome of patients with serology suggestive of past hepatitis B virus infection during antitumor necrosis factor therapy for psoriasis. Int J Dermatol 2014;53:909-11. [PMID: 24673290 DOI: 10.1111/ijd.12313] [Cited by in Crossref: 9] [Cited by in F6Publishing: 10] [Article Influence: 1.1] [Reference Citation Analysis]
49 Sagnelli C, Macera M, Pisaturo M, Zampino R, Coppola M, Sagnelli E. Occult HBV infection in the oncohematological setting. Infection. 2016;44:575-582. [PMID: 27076347 DOI: 10.1007/s15010-016-0891-1] [Cited by in Crossref: 9] [Cited by in F6Publishing: 10] [Article Influence: 1.5] [Reference Citation Analysis]
50 Hilal T, Gea-banacloche JC, Leis JF. Chronic lymphocytic leukemia and infection risk in the era of targeted therapies: Linking mechanisms with infections. Blood Reviews 2018;32:387-99. [DOI: 10.1016/j.blre.2018.03.004] [Cited by in Crossref: 25] [Cited by in F6Publishing: 22] [Article Influence: 6.3] [Reference Citation Analysis]
51 Ullmann AJ, Schmidt-Hieber M, Bertz H, Heinz WJ, Kiehl M, Krüger W, Mousset S, Neuburger S, Neumann S, Penack O, Silling G, Vehreschild JJ, Einsele H, Maschmeyer G; Infectious Diseases Working Party of the German Society for Hematology and Medical Oncology (AGIHO/DGHO) and the DAG-KBT (German Working Group for Blood and Marrow Transplantation). Infectious diseases in allogeneic haematopoietic stem cell transplantation: prevention and prophylaxis strategy guidelines 2016. Ann Hematol 2016;95:1435-55. [PMID: 27339055 DOI: 10.1007/s00277-016-2711-1] [Cited by in Crossref: 106] [Cited by in F6Publishing: 80] [Article Influence: 17.7] [Reference Citation Analysis]
52 Fylaktou A, Daoudaki M, Dimou V, Sianou E, Papaventsis D, Mavrovouniotis I, Fouzas I, Papanikolaou V. Hepatitis B Reactivation in a Renal Transplant Patient Due to a Surface Antigen Mutant Strain: A Case Report. Transplantation Proceedings 2012;44:2773-5. [DOI: 10.1016/j.transproceed.2012.09.011] [Cited by in Crossref: 4] [Cited by in F6Publishing: 4] [Article Influence: 0.4] [Reference Citation Analysis]
53 Sagnelli C, Sica A, Creta M, Borsetti A, Ciccozzi M, Sagnelli E. Prevention of HBV Reactivation in Hemato-Oncologic Setting during COVID-19. Pathogens 2022;11:567. [DOI: 10.3390/pathogens11050567] [Reference Citation Analysis]
54 Tse E, Kwong Y. Practical management of natural killer/T-cell lymphoma. Current Opinion in Oncology 2012;24:480-6. [DOI: 10.1097/cco.0b013e3283556142] [Cited by in Crossref: 21] [Cited by in F6Publishing: 10] [Article Influence: 2.1] [Reference Citation Analysis]
55 Lopetuso LR, Mocci G, Marzo M, D'Aversa F, Rapaccini GL, Guidi L, Armuzzi A, Gasbarrini A, Papa A. Harmful Effects and Potential Benefits of Anti-Tumor Necrosis Factor (TNF)-α on the Liver. Int J Mol Sci 2018;19:E2199. [PMID: 30060508 DOI: 10.3390/ijms19082199] [Cited by in Crossref: 21] [Cited by in F6Publishing: 21] [Article Influence: 5.3] [Reference Citation Analysis]
56 Tsutsumi Y, Yamamoto Y, Tanaka J, Asaka M, Imamura M, Masauzi N. Prevention of hepatitis B virus reactivation under rituximab therapy. Immunotherapy. 2009;1:1053-1061. [PMID: 20635919 DOI: 10.2217/imt.09.59] [Cited by in Crossref: 14] [Cited by in F6Publishing: 13] [Article Influence: 1.3] [Reference Citation Analysis]
57 Candotti D, El Chaar M, Allain J. Transfusion transmission of hepatitis B virus: still learning more about it: Transfusion transmission of hepatitis B virus. ISBT Science Series 2011;6:234-40. [DOI: 10.1111/j.1751-2824.2011.01493.x] [Cited by in Crossref: 4] [Cited by in F6Publishing: 5] [Article Influence: 0.4] [Reference Citation Analysis]
58 Dyson JK, Jopson L, Ng S, Lowery M, Harwood J, Waugh S, Valappil M, McPherson S. Improving testing for hepatitis B before treatment with rituximab. Eur J Gastroenterol Hepatol 2016;28:1172-8. [PMID: 27388147 DOI: 10.1097/MEG.0000000000000689] [Cited by in Crossref: 11] [Cited by in F6Publishing: 6] [Article Influence: 2.2] [Reference Citation Analysis]
59 Mastroianni CM, Lichtner M, Citton R, Borgo CD, Rago A, Martini H, Cimino G, Vullo V. Current trends in management of hepatitis B virus reactivation in the biologic therapy era. World J Gastroenterol 2011; 17(34): 3881-3887 [PMID: 22025876 DOI: 10.3748/wjg.v17.i34.3881] [Cited by in CrossRef: 36] [Cited by in F6Publishing: 39] [Article Influence: 3.3] [Reference Citation Analysis]
60 Marignani M, Gigante E, Begini P, Marzano A, di Fonzo M, Deli I, Gallina S, Cox MC, Delle Fave G. Patients with hematological malignancies and serological signs of prior resolved hepatitis B. World J Gastrointest Oncol 2012; 4(3): 37-45 [PMID: 22468182 DOI: 10.4251/wjgo.v4.i3.37] [Cited by in CrossRef: 7] [Cited by in F6Publishing: 6] [Article Influence: 0.7] [Reference Citation Analysis]
61 Cerva C, Colagrossi L, Maffongelli G, Salpini R, Di Carlo D, Malagnino V, Battisti A, Ricciardi A, Pollicita M, Bianchi A, Picardi A, Cudillo L, Cerretti R, De Angelis G, Cantonetti M, Andreoni M, Perno CF, Arcese W, Svicher V, Sarmati L. Persistent risk of HBV reactivation despite extensive lamivudine prophylaxis in haematopoietic stem cell transplant recipients who are anti-HBc-positive or HBV-negative recipients with an anti-HBc-positive donor. Clin Microbiol Infect 2016;22:946.e1-8. [PMID: 27475741 DOI: 10.1016/j.cmi.2016.07.021] [Cited by in Crossref: 19] [Cited by in F6Publishing: 18] [Article Influence: 3.2] [Reference Citation Analysis]
62 Gentile G, Foà R. Viral infections associated with the clinical use of monoclonal antibodies. Clinical Microbiology and Infection 2011;17:1769-75. [DOI: 10.1111/j.1469-0691.2011.03680.x] [Cited by in Crossref: 13] [Cited by in F6Publishing: 12] [Article Influence: 1.2] [Reference Citation Analysis]
63 Papamichalis P, Alexiou A, Boulbou M, Dalekos GN, Rigopoulou EI. Reactivation of resolved hepatitis B virus infection after immunosuppression: is it time to adopt pre-emptive therapy? Clin Res Hepatol Gastroenterol. 2012;36:84-93. [PMID: 21920838 DOI: 10.1016/j.clinre.2011.07.018] [Cited by in Crossref: 15] [Cited by in F6Publishing: 15] [Article Influence: 1.4] [Reference Citation Analysis]
64 Oh MJ, Lee HJ. A study of hepatitis B virus reactivation associated with rituximab therapy in real-world clinical practice: a single-center experience. Clin Mol Hepatol. 2013;19:51-59. [PMID: 23593610 DOI: 10.3350/cmh.2013.19.1.51] [Cited by in Crossref: 20] [Cited by in F6Publishing: 21] [Article Influence: 2.2] [Reference Citation Analysis]
65 Inamoto Y, Lee SJ. Late effects of blood and marrow transplantation. Haematologica. 2017;102:614-625. [PMID: 28232372 DOI: 10.3324/haematol.2016.150250] [Cited by in Crossref: 75] [Cited by in F6Publishing: 62] [Article Influence: 15.0] [Reference Citation Analysis]
66 Chakrabarti S, Mukherjee S. Prevention and treatment of hepatitis virus infections in hematopoietic stem cell transplant recipients. Mediterr J Hematol Infect Dis. 2009;1:e2009017. [PMID: 21415956 DOI: 10.4084/MJHID.2009.017] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.1] [Reference Citation Analysis]
67 Cooper N, Arnold DM. The effect of rituximab on humoral and cell mediated immunity and infection in the treatment of autoimmune diseases. Br J Haematol. 2010;149:3-13. [PMID: 20151975 DOI: 10.1111/j.1365-2141.2010.08076.x] [Cited by in Crossref: 92] [Cited by in F6Publishing: 96] [Article Influence: 7.7] [Reference Citation Analysis]
68 Liu YC, Hsu CM, Hsiao SY, Hsiao HH. Hepatitis B Virus Infection in Patients Receiving Allogeneic Hematopoietic Stem Cell Transplantation. J Pers Med 2021;11:1108. [PMID: 34834460 DOI: 10.3390/jpm11111108] [Reference Citation Analysis]
69 Sandherr M, Hentrich M, von Lilienfeld-Toal M, Massenkeil G, Neumann S, Penack O, Biehl L, Cornely OA. Antiviral prophylaxis in patients with solid tumours and haematological malignancies--update of the Guidelines of the Infectious Diseases Working Party (AGIHO) of the German Society for Hematology and Medical Oncology (DGHO). Ann Hematol 2015;94:1441-50. [PMID: 26193852 DOI: 10.1007/s00277-015-2447-3] [Cited by in Crossref: 65] [Cited by in F6Publishing: 45] [Article Influence: 9.3] [Reference Citation Analysis]
70 Turker K, Oksuzoglu B, Balci E, Uyeturk U, Hascuhadar M. Awareness of hepatitis B virus reactivation among physicians authorized to prescribe chemotherapy. Eur J Intern Med 2013;24:e90-2. [PMID: 23953849 DOI: 10.1016/j.ejim.2013.07.008] [Cited by in Crossref: 7] [Cited by in F6Publishing: 5] [Article Influence: 0.8] [Reference Citation Analysis]
71 Moses SE, Lim Z, Zuckerman MA. Hepatitis B virus infection: pathogenesis, reactivation and management in hematopoietic stem cell transplant recipients. Expert Rev Anti Infect Ther. 2011;9:891-899. [PMID: 21973301 DOI: 10.1586/eri.11.105] [Cited by in Crossref: 11] [Cited by in F6Publishing: 11] [Article Influence: 1.1] [Reference Citation Analysis]
72 Zachou K, Sarantopoulos A, Gatselis NK, Vassiliadis T, Gabeta S, Stefos A, Saitis A, Boura P, Dalekos GN. Hepatitis B virus reactivation in hepatitis B virus surface antigen negative patients receiving immunosuppression: A hidden threat. World J Hepatol 2013; 5(7): 387-392 [PMID: 23898372 DOI: 10.4254/wjh.v5.i7.387] [Cited by in Crossref: 24] [Cited by in F6Publishing: 19] [Article Influence: 2.7] [Reference Citation Analysis]
73 Cao X, Wang Y, Li P, Huang W, Lu X, Lu H. HBV Reactivation During the Treatment of Non-Hodgkin Lymphoma and Management Strategies. Front Oncol 2021;11:685706. [PMID: 34277431 DOI: 10.3389/fonc.2021.685706] [Cited by in F6Publishing: 1] [Reference Citation Analysis]
74 Park JJ, Wong DK, Wahed AS, Lee WM, Feld JJ, Terrault N, Khalili M, Sterling RK, Kowdley KV, Bzowej N, Lau DT, Kim WR, Smith C, Carithers RL, Torrey KW, Keith JW, Levine DL, Traum D, Ho S, Valiga ME, Johnson GS, Doo E, Lok AS, Chang KM;  Hepatitis B Research Network. Hepatitis B Virus--Specific and Global T-Cell Dysfunction in Chronic Hepatitis B.. Gastroenterology. 2016;150:684-695.e5. [PMID: 26684441 DOI: 10.1053/j.gastro.2015.11.050] [Cited by in Crossref: 98] [Cited by in F6Publishing: 99] [Article Influence: 14.0] [Reference Citation Analysis]
75 Gea-Banacloche JC. Rituximab-associated infections. Semin Hematol 2010;47:187-98. [PMID: 20350666 DOI: 10.1053/j.seminhematol.2010.01.002] [Cited by in Crossref: 166] [Cited by in F6Publishing: 143] [Article Influence: 13.8] [Reference Citation Analysis]
76 Laurenti L, Autore F, Innocenti I, Vannata B, Piccirillo N, Sorà F, Speziale D, Pompili M, Efremov D, Sica S. Prevalence, characteristics and management of occult hepatitis B virus infection in patients with chronic lymphocytic leukemia: a single center experience. Leuk Lymphoma 2015;56:2841-6. [PMID: 25682966 DOI: 10.3109/10428194.2015.1017822] [Cited by in Crossref: 9] [Cited by in F6Publishing: 9] [Article Influence: 1.3] [Reference Citation Analysis]
77 Urbani S, Fagnoni F, Missale G, Franchini M. The role of anti-core antibody response in the detection of occult hepatitis B virus infection. Clin Chem Lab Med. 2010;48:23-29. [PMID: 19919328 DOI: 10.1515/cclm.2010.002] [Cited by in Crossref: 32] [Cited by in F6Publishing: 22] [Article Influence: 2.7] [Reference Citation Analysis]
78 Koo YX, Tay M, Teh YE, Teng D, Tan DS, Tan IB, Tai DW, Quek R, Tao M, Lim ST. Risk of hepatitis B virus (HBV) reactivation in hepatitis B surface antigen negative/hepatitis B core antibody positive patients receiving rituximab-containing combination chemotherapy without routine antiviral prophylaxis. Ann Hematol. 2011;90:1219-1223. [PMID: 21520001 DOI: 10.1007/s00277-011-1241-0] [Cited by in Crossref: 77] [Cited by in F6Publishing: 71] [Article Influence: 7.0] [Reference Citation Analysis]
79 Tsutsumi Y, Yamamoto Y, Shimono J, Ohhigashi H, Teshima T. Hepatitis B virus reactivation with rituximab-containing regimen. World J Hepatol 2013; 5(11): 612-620 [PMID: 24303089 DOI: 10.4254/wjh.v5.i11.612] [Cited by in Crossref: 19] [Cited by in F6Publishing: 15] [Article Influence: 2.1] [Reference Citation Analysis]
80 Hwang JP, Fisch MJ, Lok AS, Zhang H, Vierling JM, Suarez-Almazor ME. Trends in hepatitis B virus screening at the onset of chemotherapy in a large US cancer center. BMC Cancer 2013;13:534. [PMID: 24209764 DOI: 10.1186/1471-2407-13-534] [Cited by in Crossref: 22] [Cited by in F6Publishing: 21] [Article Influence: 2.4] [Reference Citation Analysis]
81 Vassilopoulos D. Should we routinely treat patients with autoimmune/rheumatic diseases and chronic hepatitis B virus infection starting biologic therapies with antiviral agents? Yes. Eur J Intern Med. 2011;22:572-575. [PMID: 22075282 DOI: 10.1016/j.ejim.2011.09.001] [Cited by in Crossref: 14] [Cited by in F6Publishing: 14] [Article Influence: 1.3] [Reference Citation Analysis]
82 Christopeit M, Weber T, Abendroth J, Dollinger M, Lübbert C, Oehme A, Kekulé AS, Behre G. HBs seroconversion in a patient with acute hepatitis B treated with entecavir during immunosuppression against severe bronchiolitis obliterans in the course of chronic graft versus host disease. Journal of Clinical Virology 2010;48:218-9. [DOI: 10.1016/j.jcv.2010.03.009] [Cited by in Crossref: 4] [Cited by in F6Publishing: 4] [Article Influence: 0.3] [Reference Citation Analysis]
83 Lee J, Park JY, Kim DG, Lee JY, Kim BS, Kim MS, Il Kim S, Kim YS, Huh KH. Effects of rituximab dose on hepatitis B reactivation in patients with resolved infection undergoing immunologic incompatible kidney transplantation. Sci Rep 2018;8. [DOI: 10.1038/s41598-018-34111-5] [Cited by in Crossref: 8] [Cited by in F6Publishing: 3] [Article Influence: 2.0] [Reference Citation Analysis]
84 Arnold DM, Crowther MA, Meyer RM, Carruthers J, Ditomasso J, Heddle NM, McLeod A, Kelton JG. Misleading hepatitis B test results due to intravenous immunoglobulin administration: implications for a clinical trial of rituximab in immune thrombocytopenia. Transfusion 2010;50:2577-81. [PMID: 20576011 DOI: 10.1111/j.1537-2995.2010.02766.x] [Cited by in Crossref: 31] [Cited by in F6Publishing: 29] [Article Influence: 2.8] [Reference Citation Analysis]
85 Sasadeusz J, Grigg A, Hughes PD, Lee Lim S, Lucas M, McColl G, McLachlan SA, Peters MG, Shackel N, Slavin M, Sundararajan V, Thompson A, Doyle J, Rickard J, De Cruz P, Gish RG, Visvanathan K. Screening and Prophylaxis to Prevent Hepatitis B Reactivation: Transplant Recipients. Clin Liver Dis 2019;23:493-509. [PMID: 31266623 DOI: 10.1016/j.cld.2019.04.010] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.3] [Reference Citation Analysis]
86 Eberhard JM, Angin M, Passaes C, Salgado M, Monceaux V, Knops E, Kobbe G, Jensen B, Christopeit M, Kröger N, Vandekerckhove L, Badiola J, Bandera A, Raj K, van Lunzen J, Hütter G, Kuball JHE, Martinez-Laperche C, Balsalobre P, Kwon M, Díez-Martín JL, Nijhuis M, Wensing A, Martinez-Picado J, Schulze Zur Wiesch J, Sáez-Cirión A. Vulnerability to reservoir reseeding due to high immune activation after allogeneic hematopoietic stem cell transplantation in individuals with HIV-1. Sci Transl Med 2020;12:eaay9355. [PMID: 32376772 DOI: 10.1126/scitranslmed.aay9355] [Cited by in Crossref: 2] [Cited by in F6Publishing: 1] [Article Influence: 2.0] [Reference Citation Analysis]
87 Adkins BD, Booth GS, Vasu S. Transfusion support for stem cell transplant recipients. Semin Hematol 2020;57:51-6. [PMID: 32892843 DOI: 10.1053/j.seminhematol.2020.07.001] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.5] [Reference Citation Analysis]
88 Liu CY, Chandrasekar PH, Masood A, Schiffer CA. Adherence to hepatitis B screening and prophylactic lamivudine for prevention of rituximab-associated hepatitis B reactivation. J Oncol Pharm Pract 2013;19:18-23. [PMID: 22635416 DOI: 10.1177/1078155212447975] [Cited by in Crossref: 7] [Cited by in F6Publishing: 8] [Article Influence: 0.7] [Reference Citation Analysis]
89 Çeneli &, Özkurt ZN, Acar K, Rota S, Akı ŞZ, Yeğin ZA, Yağcı M, Özenirler S, Sucak GT. Hepatitis B-related events in autologous hematopoietic stem cell transplantation recipients. World J Gastroenterol 2010; 16(14): 1765-1771 [PMID: 20380010 DOI: 10.3748/wjg.v16.i14.1765] [Cited by in CrossRef: 18] [Cited by in F6Publishing: 18] [Article Influence: 1.5] [Reference Citation Analysis]
90 Riedell P, Carson KR. A drug safety evaluation of rituximab and risk of hepatitis B. Expert Opin Drug Saf 2014;13:977-87. [PMID: 24821316 DOI: 10.1517/14740338.2014.918948] [Cited by in Crossref: 10] [Cited by in F6Publishing: 7] [Article Influence: 1.3] [Reference Citation Analysis]
91 Genet P, Touahri T, Morel V. Treatment of viral hepatitis B infection in patients receiving intensive immunosuppressive therapies. Blood 2009;113:6034-6034. [DOI: 10.1182/blood-2009-04-215061] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 0.2] [Reference Citation Analysis]
92 Lunel-Fabiani F, Masson C, Ducancelle A. Systemic diseases and biotherapies: understanding, evaluating, and preventing the risk of hepatitis B reactivation. Joint Bone Spine. 2014;81:478-484. [PMID: 24561021 DOI: 10.1016/j.jbspin.2014.01.015] [Cited by in Crossref: 19] [Cited by in F6Publishing: 13] [Article Influence: 2.4] [Reference Citation Analysis]
93 Hay AE, Meyer RM. Hepatitis B, rituximab, screening, and prophylaxis: effectiveness and cost effectiveness. J Clin Oncol. 2012;30:3155-3157. [PMID: 22891267 DOI: 10.1200/jco.2012.43.7509] [Cited by in Crossref: 8] [Cited by in F6Publishing: 3] [Article Influence: 0.8] [Reference Citation Analysis]
94 Hamadani M, Craig M, Awan FT, Devine SM. How we approach patient evaluation for hematopoietic stem cell transplantation. Bone Marrow Transplant. 2010;45:1259-1268. [PMID: 20479713 DOI: 10.1038/bmt.2010.94] [Cited by in Crossref: 54] [Cited by in F6Publishing: 45] [Article Influence: 4.5] [Reference Citation Analysis]
95 Tuncer HH, Rana N, Milani C, Darko A, Al-Homsi SA. Gastrointestinal and hepatic complications of hematopoietic stem cell transplantation. World J Gastroenterol 2012; 18(16): 1851-1860 [PMID: 22563164 DOI: 10.3748/wjg.v18.i16.1851] [Cited by in CrossRef: 62] [Cited by in F6Publishing: 51] [Article Influence: 6.2] [Reference Citation Analysis]
96 Randhawa JK, Ferrajoli A. A review of supportive care and recommended preventive approaches for patients with chronic lymphocytic leukemia. Expert Rev Hematol 2016;9:235-44. [PMID: 26652692 DOI: 10.1586/17474086.2016.1129893] [Cited by in Crossref: 6] [Cited by in F6Publishing: 4] [Article Influence: 1.0] [Reference Citation Analysis]
97 Makvandi M. Update on occult hepatitis B virus infection. World J Gastroenterol 2016; 22(39): 8720-8734 [PMID: 27818588 DOI: 10.3748/wjg.v22.i39.8720] [Cited by in CrossRef: 72] [Cited by in F6Publishing: 62] [Article Influence: 12.0] [Reference Citation Analysis]
98 Marignani M, Canzoni M, D'Amelio R, De Santis E, Pecchioli A, Delle Fave G. Should we routinely treat patients with autoimmune/rheumatic diseases and chronic hepatitis B virus infection starting biologic therapies with antiviral agents? NO. Eur J Intern Med 2011;22:576-81. [PMID: 22075283 DOI: 10.1016/j.ejim.2011.09.002] [Cited by in Crossref: 5] [Cited by in F6Publishing: 4] [Article Influence: 0.5] [Reference Citation Analysis]